Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
This study is designed to investigate the quantitative effects of sodium-free chloride supplementation on electrolyte balance, volume status, and sodium avidity in stable heart failure patients in a highly controlled environment.
Full description
The overarching goal of this study is to develop a comprehensive understanding of the biology and therapeutic potential of sodium-free chloride supplementation. While sodium homeostasis has been the focus of substantial investigation, very little research has been devoted to understanding chloride homeostasis. Thus, this proposal is designed to obtain the full spectrum of information pertaining to chloride, such as novel areas with great interest by the scientific community (i.e. modulation of the WNK-kinase system and the use of exosomes), to more practical/basic questions (i.e. what happens to sodium chloride balance when a patient is challenged with chloride).
This study is designed as a highly controlled inpatient "GCRC" arm to be compared to a real world efficacy study that has been proposed as a separate study. With extensive biobanking and analysis of samples in the inpatient setting, we will be able to deliver a great wealth of information on the biology and therapeutic potential of manipulating chloride homeostasis in heart failure.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
-
Meticulous history of medical compliance and attendance of appointments
-
Stable heart failure as defined by:
- Absence of hospitalizations for 90 days
- Stable diuretic and medical therapy for 30 days
- Opinion of the patient's treating physician (Heart Failure Cardiologist) that the patient is at optimal volume status
-
Evidence based heart failure treatment with maximally-tolerated doses of a beta blocker, ACE/ARB/neprilysin inhibitor and aldosterone antagonist
-
Ejection fraction <40%
-
Chronic loop diuretic therapy with ≥ 40 mg of furosemide equivalents
-
Serum chloride <102 mmol/L
Exclusion criteria
- Inability to commit to or comply with the rigorous outpatient or inpatient study protocol
- Use of a thiazide diuretic in the last 30 days
- History of metabolic or respiratory acidosis
- Use of metformin, acetazolamide, or any other agent that could predispose to acidosis. Patients who are on metformin may be enrolled if their metformin can be safely discontinued for the inpatient randomized periods in each arm. Any participants who have consistently elevated Blood glucose readings > 200 mg/dL while inpatient will not be enrolled.
- Serum bicarbonate level <24mmol/L
- Estimated glomerular filtration rate <30 mL/min or prior or current history of renal replacement therapy
- Anemia, as defined by Hemoglobin <8.0 g/dL at screening visit
- Urinary incontinence or significant bladder dysfunction (post-void residual at screening >100 mL
- Use of chloride containing medications that provide more than 5 mmol/day of chloride if the medication cannot be discontinued or substituted
- Appears unlikely, or unable to participate in the required study procedures, as assessed by the study PI or research RN (ex: clinically-significant psychiatric, addictive, or neurological disease)
- Inability to give written informed consent or follow study protocol
Trial design
Primary purpose
Allocation
Interventional model
Masking
20 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Central trial contact
Jeffrey M Testani; Katherine Keith
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal